


## Mefloquine

<b>Cat. No.:</b>	HY-17437
<b>CAS No.:</b>	53230-10-7
<b>Molecular Formula:</b>	C <sub>17</sub> H <sub>16</sub> F <sub>6</sub> N <sub>2</sub> O
<b>Molecular Weight:</b>	378.31
<b>Target:</b>	Parasite; Autophagy; SARS-CoV; Potassium Channel; ROS
<b>Pathway:</b>	Anti-infection; Autophagy; Membrane Transporter/Ion Channel; Protein Tyrosine Kinase/RTK
<b>Storage:</b>	Please store the product under the recommended conditions in the Certificate of Analysis.



### BIOLOGICAL ACTIVITY

<b>Description</b>	Mefloquine (Mefloquin), an orally active and potent quinoline antimalarial agent, is an anti-SARS-CoV-2 entry inhibitor. Mefloquine is also a K <sup>+</sup> channel (KvQT1/minK) antagonist with an IC <sub>50</sub> of ~1 μM. Mefloquine can be used for malaria, systemic lupus erythematosus and cancer research <sup>[1][2][3]</sup> .
<b>In Vitro</b>	Mefloquine selectively inhibits prostate cancer (PCa) cell growth with an IC <sub>50</sub> of ~10 μM. Mefloquine also induces hyperpolarization of the mitochondrial membrane potential (MMP), as well as ROS generation <sup>[2]</sup> . Mefloquine (10 μM)-mediated ROS simultaneously downregulated Akt phosphorylation and activated ERK, JNK and AMPK signaling in PC3 cells <sup>[2]</sup> . Mefloquine shows higher anti-SARS-CoV-2 activity than Hydroxychloroquine in VeroE6/TMPRSS2 and Calu-3 cells, with IC <sub>50</sub> of 1.28 μM, IC <sub>90</sub> of 2.31 μM, and IC <sub>99</sub> of 4.39 μM in VeroE6/TMPRSS2 cells. Mefloquine inhibits viral entry after viral attachment to the target cell <sup>[3]</sup> . MCE has not independently confirmed the accuracy of these methods. They are for reference only.
<b>In Vivo</b>	Mefloquine (5 mg/kg; i.p.; daily; 14 days) reverses the lower vertebral cancellous bone volume and bone formation; and has modest effects on cortical bone volume, thickness, and moment of inertia in old mice <sup>[4]</sup> . MCE has not independently confirmed the accuracy of these methods. They are for reference only.

### CUSTOMER VALIDATION

- Front Oncol. 2020 Jul 28;10:1217.
- PLoS Negl Trop Dis. 2019 Aug 20;13(8):e0007681.

See more customer validations on [www.MedChemExpress.com](http://www.MedChemExpress.com)

### REFERENCES

[1]. Kang J, et al. Interactions of the antimalarial drug mefloquine with the human cardiac potassium channels KvLQT1/minK and HERG. J Pharmacol Exp Ther. 2001 Oct;299(1):290-6.

---

[2]. Yan KH, et al. Mefloquine exerts anticancer activity in prostate cancer cells via ROS-mediated modulation of Akt, ERK, JNK and AMPK signaling. *Oncol Lett.* 2013 May;5(5):1541-1545.

[3]. Kaho Shionoya, et al. Mefloquine, a Potent Anti-severe Acute Respiratory Syndrome-Related Coronavirus 2 (SARS-CoV-2) Drug as an Entry Inhibitor in vitro. *Front Microbiol.* 2021 Apr 30;12:651403.

[4]. Rafael Pacheco-Costa, et al. Reversal of loss of bone mass in old mice treated with mefloquine. *Bone.* 2018 Sep;114:22-31.

---

**Caution: Product has not been fully validated for medical applications. For research use only.**

Tel: 609-228-6898

Fax: 609-228-5909

E-mail: [tech@MedChemExpress.com](mailto:tech@MedChemExpress.com)

Address: 1 Deer Park Dr, Suite Q, Monmouth Junction, NJ 08852, USA